Therapeutic Targeting of CSN5, a Negative Regulator of p53 and p27, in Human Hepatocellular Carcinoma
Posted Oct 31 2008 5:00pm
Description of Invention: Hepatocellular carcinoma (HCC) represents an extremely poor prognostic cancer that remains one of the most common and aggressive malignancies worldwide. Elevated expression of COP9 complex homolog subunit 5 (CSN5) in early HCC indicates that CSN5 is one of the early markers of malignant conversion. COP9 complex homolog subunit 5 (CSN5) is a multifunctional protein that interacts with a variety of proteins and targets p53 for cell degradation.
Available for licensing are CSN5 siRNAs and nucleic-acid lipid siRNA particles as cancer therapies. HCC cells treated CSN5 siRNAs inhibited HCC progression and increased apoptosis in vitro and in vivo suggesting that CSN5 is an effective target for the development of cancer treatments.
siRNA cancer therapeutics
Nucleic-acid lipid siRNA particles for targeted drug delivery
JS Lee et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004 Sept;40(3):667-676. [ PubMed abs ]
Licensing Status: Available for non-exclusive licensing.
Portfolios: Cancer Cancer - Therapeutics Cancer - Research Materials Gene Based Therapies Gene Based Therapies - Therapeutics
For Additional Information Please Contact: Patrick McCue Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: McCuepat@mail.nih.gov Phone: 301-496-7057 Fax: 301-402-0220